The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial
Open accessAbstract
Oncolytic virotherapy may be a means of improving the dismal prognosis of malignant brain tumors. The rat H-1 parvovirus (H-1PV) suppresses tumors in preclinical glioma models, through both direct oncolysis and stimulation of anticancer immune responses. This was the basis of ParvOryx01, the first phase I/IIa clinical trial of an oncolytic parvovirus in recurrent glioblastoma patients. H-1PV (escalating dose) was administered via intratumoral or intravenous injection. Tumors were resected 9 days after treatment, and virus was re-administered around the resection cavity. Primary endpoints were safety and tolerability, virus distribution, and maximum tolerated dose (MTD). Progression-free and overall survival and levels of viral and immunological markers in the tumor and peripheral blood were also investigated. H-1PV treatment was safe and well tolerated, and no MTD was reached. The virus could cross the blood-brain/tumor barrier and spread widely through the tumor. It showed favorable pharmacokinetics, induced antibody formation in a dose-dependent manner, and triggered specific T cell responses. Markers of virus replication, microglia/macrophage activation, and cytotoxic T cell infiltration were detected in infected tumors, suggesting that H-1PV may trigger an immunogenic stimulus. Median survival was extended in comparison with recent meta-analyses. Altogether, ParvOryx01 results provide an impetus for further H-1PV clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
O'Quigley, J., Pepe, M., & Fisher, L. (1990) · Biometrics · doi:10.2307/2531628 · Cited by 1,577
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Rampling, R., Cruickshank, G., Papanastassiou, V, Nicoll, J., Hadley, D., Brennan, D., Petty, R., MacLean, A., Harland, J., McKie, E., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301184 · Cited by 598
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses1
Hussain, S. F., Yang, D., Suki, D., Aldape, K., Grimm, E., & Heimberger, A. B. (2006) · Neuro-Oncology · doi:10.1215/15228517-2006-008 · Cited by 592
Going viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Harrow, S., Papanastassiou, V, Harland, J., Mabbs, R., Petty, R., Fraser, M., Hadley, D., Patterson, J., Brown, S. M., & Rampling, R. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302289 · Cited by 342
Markert, J. M., Razdan, S. N., Kuo, H.-C., Cantor, A., Knoll, A., Karrasch, M., Nabors, L. B., Markiewicz, M., Agee, B. S., Coleman, J. M., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.22 · Cited by 319
Ballman, K. V., Buckner, J. C., Brown, P. D., Giannini, C., Flynn, P. J., LaPlant, B. R., & Jaeckle, K. A. (2007) · Neuro-Oncology · doi:10.1215/15228517-2006-025 · Cited by 314
Forsyth, P., Roldán, G., George, D., Wallace, C., Palmer, C. A., Morris, D., Cairncross, G., Matthews, M. V., Markert, J., Gillespie, Y., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300403 · Cited by 278
Suchorska, B., Weller, M., Tabatabai, G., Senft, C., Hau, P., Sabel, M. C., Herrlinger, U., Ketter, R., Schlegel, U., Marosi, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov326 · Cited by 254
New viruses for cancer therapy: meeting clinical needs
Miest, T. S., & Cattaneo, R. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3140 · Cited by 220
Tattersall, P., & Bratton, J. (1983) · Journal of Virology · doi:10.1128/jvi.46.3.944-955.1983 · Cited by 205
Rutledge, W. C., Kong, J., Gao, J., Gutman, D. A., Cooper, L. A. D., Appin, C., Park, Y., Scarpace, L., Mikkelsen, T., Cohen, M. L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0551 · Cited by 200
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma
Cloughesy, T. F., Landolfi, J., Hogan, D. J., Bloomfield, S., Carter, B., Chen, C. C., Elder, J. B., Kalkanis, S. N., Kesari, S., Lai, A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9784 · Cited by 195
Parvoviruses: Small Does Not Mean Simple
Cotmore, S. F., & Tattersall, P. (2014) · Annual Review of Virology · doi:10.1146/annurev-virology-031413-085444 · Cited by 173
Microglial secreted cathepsin B induces neuronal apoptosis
Kingham, P. J., & Pocock, J. M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00146.x · Cited by 167
Geletneky, K., Huesing, J., Rommelaere, J., Schlehofer, J. R., Leuchs, B., Dahm, M., Krebs, O., Doeberitz, M. V. K., Huber, B., & Hajda, J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-99 · Cited by 159
Self-citationKicielinski, K. P., Chiocca, E. A., Yu, J. S., Gill, G. M., Coffey, M., & Markert, J. M. (2014) · Molecular Therapy · doi:10.1038/mt.2014.21 · Cited by 158
Piazza, M., Mader, C., Geletneky, K., y Calle, M. H., Weber, E., Schlehofer, J. R., Deleu, L., & Rommelaere, J. (2007) · Journal of Virology · doi:10.1128/jvi.02601-06 · Cited by 156
Self-citationClarke, J. L., Ennis, M. M., Yung, W. K. A., Chang, S., Wen, P. Y., Cloughesy, T. F., DeAngelis, L. M., Robins, H. I., Lieberman, F. S., Fine, H. A., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor110 · Cited by 120
Oncolytic parvoviruses as cancer therapeutics
Rommelaere, J., Geletneky, K., Angelova, A. L., Daeffler, L., Dinsart, C., Kiprianova, I., Schlehofer, J. R., & Raykov, Z. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.02.011 · Cited by 118
Self-citationNüesch, J. P. F., Lacroix, J., Marchini, A., & Rommelaere, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2325 · Cited by 106
Self-citationGeletneky, K., Kiprianova, I., Ayache, A., Koch, R., y Calle, M. H., Deleu, L., Sommer, C., Thomas, N., Rommelaere, J., & Schlehofer, J. R. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq023 · Cited by 98
Self-citationMicroglia isolated from patients with glioma gain antitumor activities on poly (I:C) stimulation
Kees, T., Lohr, J., Noack, J., Mora-Rodríguez, R. A., Gdynia, G., Toedt, G., Ernst, A., Radlwimmer, B., Falk, C. S., Herold‐Mende, C. C., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor182 · Cited by 88
FISHing with locked nucleic acids (LNA): evaluation of different LNA/DNA mixmers
Silahtaroglu, A., Tommerup, N., & Vissing, H. (2003) · Molecular and Cellular Probes · doi:10.1016/s0890-8508(03)00048-3 · Cited by 71
Cockle, J. V., Rajani, K. R., Zaidi, S., Kottke, T. J., Thompson, J., Díaz, R. M., Shim, K. G., Peterson, T., Parney, I. F., Short, S. C., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov173 · Cited by 65
Hwang, S., Yoo, B. C., Jung, J., Oh, E., Hwang, J., Shin, J., Kim, S., Cha, S., & Han, I. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.08.011 · Cited by 58
H-1 Virus Viremia in the Human.
Toolan, H. W., Saunders, E. L., Southam, C. M., Moore, A. E., & LEVIN, A. G. (1965) · Experimental Biology and Medicine · doi:10.3181/00379727-119-30278 · Cited by 47
To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses
Cassady, K. A., Haworth, K. B., Jackson, J., Markert, J. M., & Cripe, T. P. (2016) · Viruses · doi:10.3390/v8020043 · Cited by 46
Grekova, S. P., Aprahamian, M., Giese, N. A., Schmitt, S., Giese, T., Falk, C. S., Daeffler, L., Cziepluch, C., Rommelaere, J., & Raykov, Z. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.12.13455 · Cited by 44
Self-citationActivation of a Helper and Not Regulatory Human CD4+ T Cell Response by Oncolytic H-1 Parvovirus
Moralès, O., Richard, A. S., Martin, N., Mrizak, D., Sénéchal, M., Miroux, C., Pancré, V., Rommelaere, J., Caillet-Fauquet, P., de Launoit, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032197 · Cited by 31
Self-citationNehmé, B., Henry, M., & Mouginot, D. (2011) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2011.01.018 · Cited by 21
Standardized large-scale H-1PV production process with efficient quality and quantity monitoring
Leuchs, B., Roscher, M., Müller, M. C., Kürschner, K., & Rommelaere, J. (2015) · Journal of Virological Methods · doi:10.1016/j.jviromet.2015.11.022 · Cited by 16
Self-citation
Cited by
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Cancer vaccines: the next immunotherapy frontier
Lin, M. J., Svensson-Arvelund, J., Lubitz, G. S., Marabelle, A., Melero, I., Brown, B. D., & Brody, J. D. (2022) · Nature Cancer · doi:10.1038/s43018-022-00418-6 · Cited by 843
Challenges in glioblastoma research: focus on the tumor microenvironment
Bikfalvi, A., da Costa, C. A., Avril, T., Barnier, J.-V., Bauchet, L., Brisson, L., Cartron, P. F., Castel, H., Chevet, E., Chneiweiss, H., et al. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2022.09.005 · Cited by 302
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms
Chang, C., Chavarro, V. S., Gerstl, J. V. E., Blitz, S. E., Spanehl, L., Dubinski, D., Valdes, P. A., Tran, L. N., Gupta, S., Esposito, L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126733 · Cited by 45
Metadata
- Authors
- Geletneky, K., Hajda, J., Angelova, A. L., Leuchs, B., Capper, D., Bartsch, A. J., Neumann, J.-O., Schöning, T., Hüsing, J., Beelte, B., Kiprianova, I., Roscher, M., Bhat, R., von Deimling, A., Brück, W., Just, A., Frehtman, V., Löbhard, S., Terletskaia-Ladwig, E., Fry, J., Jochims, K., Daniel, V., Krebs, O., Dahm, M., Huber, B., Unterberg, A., & Rommelaere, J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 25
- Issue
- 12
- Pages
- 2620-2634
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2748739447
- Cited by
- 260
- References
- 40
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.